ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,068 | $993 | $654 | $580 |
| - Cash | $145 | $221 | $48 | $100 |
| + Debt | $624 | $286 | $287 | $287 |
| Enterprise Value | $1,547 | $1,057 | $892 | $767 |
| Revenue | $614 | $487 | $316 | $216 |
| % Growth | 26.2% | 53.9% | 46.4% | – |
| Gross Profit | $364 | $305 | $178 | $116 |
| % Margin | 59.3% | 62.7% | 56.1% | 53.5% |
| EBITDA | $63 | $107 | $25 | $3 |
| % Margin | 10.3% | 21.9% | 7.9% | 1.4% |
| Net Income | -$19 | $19 | -$48 | -$43 |
| % Margin | -3% | 3.9% | -15.1% | -19.7% |
| EPS Diluted | -1.04 | 0.94 | -3.05 | -3.4 |
| % Growth | -210.6% | 130.8% | 10.3% | – |
| Operating Cash Flow | $64 | $119 | -$31 | $3 |
| Capital Expenditures | -$17 | -$19 | -$16 | -$24 |
| Free Cash Flow | $47 | $100 | -$48 | -$20 |